Redeye provides its initial take on Heliospectra’s Q4 results, noting that while sales were below expectations and costs came in higher, the overall financials reflect a transitional phase for the company. Management remains positive about the outlook, citing strong market activity and a reinforced commercial strategy heading into 2025.
LÄS MER
